{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:57:00Z","timestamp":1790852220625,"version":"4.1.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82460933"],"award-info":[{"award-number":["82460933"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Oncol. Rev."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although radiotherapy (RT) and natural killer (NK) cell-based therapy have shown promising potential in the treatment of non-small cell lung cancer (NSCLC), the therapeutic efficacy and safety of their combination remain to be fully elucidated. In this study, we evaluated the efficacy and safety of combined RT and NK cell therapy and performed preliminary proteomic profiling to characterize its potential effects on the tumor immune microenvironment (TIME), providing new insights and a theoretical and clinical basis for the development of NK cell-based therapeutic strategies for NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>C57BL\/6-derived subcutaneous Lewis lung carcinoma models were established to determine the minimal effective dose of both radiotherapy and adoptively transferred natural killer cells. Based on the MED-derived findings, the mice were further randomized into five experimental groups for therapeutic efficacy evaluation: the Control group, the RT group, the NK group, the combination therapy group (RN group), and the repeated combination therapy group (RN2 group). Tumour volume and body weight were monitored longitudinally. Differentially abundant proteins were interrogated by Gene Ontology enrichment and Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway analyses to systematically describe the synergistic antitumor efficacy of differentially expressed proteins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with RT or NK cell-based immunotherapy as monotherapies, the RN group exhibited markedly enhanced tumor growth inhibition, with no overt treatment-related toxicities observed. Following the second cycle of combined therapy, mice in the RN2 group displayed a more pronounced reduction in tumor growth rate with those in the single-cycle combination cohort; notably, no significant adverse events associated with the combined regimen were detected throughout the entire experimental duration. Proteomic profiling unraveled that RT disrupted the core regulatory networks governing intracellular DNA replication and repair processes in tumor cells in a therapy-specific manner, whereas NK cell immunotherapy potently and selectively activated the classical pathway of the host complement system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Collectively, RT and NK cell therapy demonstrate superior synergistic efficacy and no overt toxicity was observed, with repeated treatments further delaying tumor progression. Mechanistically, proteomics shows that RT disrupts DNA replication\/repair networks, whereas NK cell therapy was associated with upregulation of multiple complement components, including those belonging to the classical and lectin pathways, suggesting a potential involvement of these pathways.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/or.2026.1853377","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:06:54Z","timestamp":1790849214000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the immune enhancement effect of radiotherapy combined with NK cells on non-small cell lung cancer based on proteomics technology"],"prefix":"10.3389","volume":"20","author":[{"given":"Cui","family":"Chang","sequence":"first","affiliation":[{"name":"Graduate School, Guangxi University of Chinese Medicine","place":["Nanning, Guangxi, China"]},{"name":"The Second Affiliated Hospital of Guangxi University of Chinese Medicine","place":["Nanning, Guangxi, China"]},{"name":"The Second School of Clinical Medicine, Guangdong Medical University","place":["Dongguan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tang","family":"Youming","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangxi University of Chinese Medicine","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Ying","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangxi University of Chinese Medicine","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Ningning","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangxi University of Chinese Medicine","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Chunhui","sequence":"additional","affiliation":[{"name":"Graduate School, Guangxi University of Chinese Medicine","place":["Nanning, Guangxi, China"]},{"name":"The Second Affiliated Hospital of Guangxi University of Chinese Medicine","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Dekai","sequence":"additional","affiliation":[{"name":"Graduate School, Guangxi University of Chinese Medicine","place":["Nanning, Guangxi, China"]},{"name":"The Second Affiliated Hospital of Guangxi University of Chinese Medicine","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Mei","sequence":"additional","affiliation":[{"name":"Graduate School, Guangxi University of Chinese Medicine","place":["Nanning, Guangxi, China"]},{"name":"The Second Affiliated Hospital of Guangxi University of Chinese Medicine","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Qiyuan","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangxi University of Chinese Medicine","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Gechen","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangxi University of Chinese Medicine","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Fasheng","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangxi University of Chinese Medicine","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Jibing","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guangxi University of Chinese Medicine","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S1470-2045(23)00444-8","article-title":"Global variations in lung cancer incidence by histological subtype in 2020: a population-based study","volume":"24","author":"Zhang","year":"2023","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","article-title":"Advances in molecular pathology and therapy of non-small cell lung cancer","volume":"10","author":"Huang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"6559","DOI":"10.3390\/ijms26146559","article-title":"Mechanisms underlying radioresistance and reversal strategies in non-small cell lung cancer","volume":"26","author":"Zhao","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1603757","DOI":"10.3389\/fimmu.2025.1603757","article-title":"CAR-NK cells: harnessing the power of natural killers for advanced cancer therapy","volume":"16","author":"Dos Reis","year":"2025","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"612072","DOI":"10.3389\/fimmu.2020.612072","article-title":"Advances in hypofractionated irradiation-induced immunosuppression of tumor microenvironment","volume":"11","author":"Wang","year":"2020","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/cac2.12226","article-title":"Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: challenges and updates","volume":"41","author":"Shang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e011330","DOI":"10.1136\/jitc-2024-011330","article-title":"Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy","volume":"13","author":"Reindl","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1777651","DOI":"10.1080\/2162402X.2020.1777651","article-title":"Immunotherapy with NK cells: recent developments in gene modification open up new avenues","volume":"9","author":"Reindl","year":"2020","journal-title":"Oncoimmunology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","article-title":"Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1298683","DOI":"10.3389\/fimmu.2023.1298683","article-title":"Synergistic treatment strategy: combining CAR-NK cell therapy and radiotherapy to combat solid tumors","volume":"14","author":"He","year":"2023","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.7150\/jca.44622","article-title":"HDAC inhibitor, CG-745, enhances the anti-cancer effect of Anti-PD-1 immune checkpoint inhibitor by modulation of the immune microenvironment","volume":"11","author":"Kim","year":"2020","journal-title":"J Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-020-00940-z","article-title":"SBRT combined with PD-1\/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges","volume":"13","author":"Chen","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"111233","DOI":"10.1016\/j.isci.2024.111233","article-title":"Tumor stage-driven disruption of NK cell maturation in human and murine tumors","volume":"27","author":"Russick","year":"2024","journal-title":"iScience"},{"key":"B16","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.it.2018.06.001","article-title":"Immunological mechanisms responsible for radiation-induced abscopal effect","volume":"39","author":"Rodriguez-Ruiz","year":"2018","journal-title":"Trends Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"723609","DOI":"10.3389\/fimmu.2021.723609","article-title":"The combination of radiotherapy with immunotherapy and potential predictive biomarkers for treatment of non-small cell lung cancer patients","volume":"12","author":"Meng","year":"2021","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"bpaf015","DOI":"10.1093\/biomethods\/bpaf015","article-title":"Protocol for isolation and expansion of natural killer cells from human peripheral blood scalable for clinical applications","volume":"10","author":"Kundu","year":"2025","journal-title":"Biol Methods Protoc"},{"key":"B19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13046-020-01688-7","article-title":"Cancer-derived exosomal TRIM59 regulates macrophage NLRP3 inflammasome activation to promote lung cancer progression","volume":"39","author":"Liang","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"110652","DOI":"10.1016\/j.intimp.2023.110652","article-title":"Intermittent hypoxia inhibits anti-tumor immune response via regulating PD-L1 expression in lung cancer cells and tumor-associated macrophages","volume":"122","author":"Cui","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"9955","DOI":"10.2147\/DDDT.S531106","article-title":"Hirsutella sinensis fungus enhances CD8(+) T cell anti-tumor activity in NSCLC via modulating the IL-10\/STAT3\/STAT1 axis","volume":"19","author":"Zhang","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.7150\/thno.52435","article-title":"ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation","volume":"11","author":"Chen","year":"2021","journal-title":"Theranostics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.3390\/ijms21134585","article-title":"Brachytherapy in a single dose of 10Gy as an \u201cin situ\u201d vaccination","volume":"21","author":"Jarosz-Biej","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"31163","DOI":"10.1038\/s41598-024-82451-2","article-title":"Impact of antiphospholipid syndrome on placenta and uterine NK cell function: insights from a mouse model","volume":"14","author":"Martirosyan","year":"2024","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.20892\/j.issn.2095-3941.2024.0218","article-title":"Potential treatment approaches for malignant peritoneal mesothelioma: in vivo and in vitro experimental study of natural killer cell immunotherapy","volume":"21","author":"Wu","year":"2024","journal-title":"Cancer Biol Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e2300340","DOI":"10.1002\/pmic.202300340","article-title":"Improved breast milk proteome coverage by DIA based LC-MS\/MS method","volume":"24","author":"Viitaharju","year":"2024","journal-title":"Proteomics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s11864-024-01260-x","article-title":"Efficacy and mechanism of combining radiotherapy and immunotherapy in stage IV non-small cell lung cancer","volume":"25","author":"Wang","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: standard- Versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ijrobp.2019.12.030","article-title":"Lung stereotactic body radiation therapy and concurrent immunotherapy: a multicenter safety and toxicity analysis","volume":"108","author":"Tian","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/cam4.3718","article-title":"Safety and efficacy of PD-1\/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis","volume":"10","author":"Geng","year":"2021","journal-title":"Cancer Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S1470-2045(24)00498-4","article-title":"Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial","volume":"25","author":"Provencio","year":"2024","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"113689","DOI":"10.1016\/j.intimp.2024.113689","article-title":"Will personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR) or split-course SBRT based on systemic therapy (3S) be future directions in the field of SBRT?","volume":"146","author":"Zhou","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5923","DOI":"10.21037\/apm.2020.03.31","article-title":"Oligometastases: history of a hypothesis","volume":"10","author":"Milano","year":"2021","journal-title":"Ann Palliat Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e91213","DOI":"10.7759\/cureus.91213","article-title":"Role of complement anaphylatoxins (C3a and C5a) in lymphoma: a systematic review","volume":"17","author":"Skarentzos","year":"2025","journal-title":"Cureus"},{"key":"B36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ijrobp.2019.09.041","article-title":"Combined NK cell therapy and radiation therapy exhibit long-term therapeutic and antimetastatic effects in a human triple negative breast cancer model","volume":"108","author":"Kim","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B37","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1158\/2767-9764.crc-22-0069","article-title":"The combination of radiotherapy and complement C3a inhibition potentiates natural killer cell functions against pancreatic cancer","volume":"2","author":"Sodji","year":"2022","journal-title":"Cancer Res Commun"},{"key":"B38","doi-asserted-by":"publisher","first-page":"106761","DOI":"10.1016\/j.intimp.2020.106761","article-title":"Damage-associated molecular patterns in tumor radiotherapy","volume":"86","author":"Ashrafizadeh","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3390\/cells10040930","article-title":"Biomarkers of radiotherapy-induced immunogenic cell death","volume":"10","author":"Vaes","year":"2021","journal-title":"Cells"},{"key":"B40","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ijrobp.2023.11.023","article-title":"Direct tumor irradiation potentiates adoptive NK cell targeting against parental and stemlike cancer in human liver cancer models","volume":"119","author":"Uong","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1403395","DOI":"10.3389\/fgeed.2024.1403395","article-title":"CRISPR-Cas9 immune-evasive hESCs are rejected following transplantation into immunocompetent mice","volume":"6","author":"Frederiksen","year":"2024","journal-title":"Front Genome"},{"key":"B42","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fimmu.2015.00286","article-title":"Present and future of allogeneic natural killer cell therapy","volume":"6","author":"Lim","year":"2015","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"B44","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fcell.2020.00402","article-title":"Molecular aspects and future perspectives of cytokine-based anti-cancer immunotherapy","volume":"8","author":"Chulpanova","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41523-022-00462-6","article-title":"Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first\/second-line treatment: the NAN trial","volume":"8","author":"Li","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e010612","DOI":"10.1136\/jitc-2024-010612","article-title":"Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6\/Jak\/Stat3 in PD-L1-high lung cancer","volume":"13","author":"Jeong","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e2111900119","DOI":"10.1073\/pnas.2111900119","article-title":"Radiotherapy transiently reduces the sensitivity of cancer cells to lymphocyte cytotoxicity","volume":"119","author":"Tuomela","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B48","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1186\/s12967-025-06753-3","article-title":"Robo1 CAR-NK92 and radiotherapy exert synergistic efficacy in solid tumors","volume":"23","author":"Wu","year":"2025","journal-title":"J Transl Med"}],"container-title":["Oncology Reviews"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/or.2026.1853377\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:06:55Z","timestamp":1790849215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/or.2026.1853377\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":48,"alternative-id":["10.3389\/or.2026.1853377"],"URL":"https:\/\/doi.org\/10.3389\/or.2026.1853377","relation":{},"ISSN":["1970-5557"],"issn-type":[{"value":"1970-5557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"1853377"}}